MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 76 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $425,427 | +5.0% | 52,848 | +41.7% | 0.00% | – |
| Q2 2023 | $405,165 | -60.7% | 37,308 | -75.0% | 0.00% | – |
| Q1 2023 | $1,030,287 | +173.1% | 149,317 | +57.5% | 0.00% | – |
| Q4 2022 | $377,308 | +289.0% | 94,801 | +551.4% | 0.00% | – |
| Q3 2022 | $97,000 | +61.7% | 14,553 | +16.7% | 0.00% | – |
| Q2 2022 | $60,000 | -67.7% | 12,470 | -37.6% | 0.00% | – |
| Q1 2022 | $186,000 | -31.9% | 19,982 | -12.9% | 0.00% | – |
| Q4 2021 | $273,000 | +8.8% | 22,934 | +3.9% | 0.00% | – |
| Q3 2021 | $251,000 | +3.7% | 22,082 | +63.8% | 0.00% | – |
| Q2 2021 | $242,000 | -46.2% | 13,483 | -53.7% | 0.00% | – |
| Q1 2021 | $450,000 | +192.2% | 29,094 | +129.9% | 0.00% | – |
| Q4 2020 | $154,000 | +26.2% | 12,653 | +34.0% | 0.00% | – |
| Q3 2020 | $122,000 | – | 9,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |